PG
ALXN

PEAK6 Group’s Alexion Pharmaceuticals ALXN Stock Holding History

PEAK6 Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		$2.69M Buy
21,645
+6,446
+42% +$753K 0.01% 1144
2018
Q1 		$1.69M Sell
15,199
-4,804
-24% -$574K 0.01% 1512
2017
Q4 		$2.39M Buy
20,003
+3,744
+23% +$456K 0.01% 1267
2017
Q3 		$2.28M Sell
16,259
-58,596
-78% -$7.96M 0.01% 1277
2017
Q2 		$9.11M Buy
74,855
+57,784
+338% +$6.73M 0.05% 421
2017
Q1 		$2.07M Buy
+17,071
New +$2.2M 0.02% 1114
2016
Q3 		– Sell
-19,592
Closed -$2.52M – 4901
2016
Q2 		$2.29M Buy
+19,592
New +$2.78M 0.02% 1143
2015
Q4 		– Sell
-31,920
Closed -$5.58M – 5508
2015
Q3 		$4.99M Buy
31,920
+13,679
+75% +$2.5M 0.03% 890
2015
Q2 		$3.3M Sell
18,241
-8,064
-31% -$1.39M 0.02% 1111
2015
Q1 		$4.56M Buy
26,305
+16,991
+182% +$3.08M 0.03% 731
2014
Q4 		$1.72M Sell
9,314
-25,610
-73% -$4.75M 0.01% 1458
2014
Q3 		$5.79M Buy
34,924
+14,406
+70% +$2.37M 0.04% 568
2014
Q2 		$3.21M Sell
20,518
-19,492
-49% -$3.08M 0.03% 778
2014
Q1 		$6.09M Buy
40,010
+37,747
+1,668% +$6M 0.05% 511
2013
Q4 		$301K Sell
2,263
-34,663
-94% -$4.16M ﹤0.01% 3148
2013
Q3 		$2.15M Buy
36,926
+31,226
+548% +$3.43M 0.01% 1478
2013
Q2 		$526 Buy
+5,700
New +$549K ﹤0.01% 2727

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

PEAK6 Group's ALXN Position: Q2 2018 in Review

PEAK6 Group increased its Alexion Pharmaceuticals (ALXN) stake by 42% in Q2 2018, buying an estimated $753K and bringing the position to 21,645 shares worth $2.69M. The position accounts for 0.01% of the portfolio, ranked #1144.

PEAK6 Group first reported a position in ALXN in Q2 2013 and has held it in 17 quarters since. The position peaked at $9.11M in Q2 2017. 600 funds tracked by Wall St. Rank hold ALXN as of Q2 2018.

  • PEAK6 Group held 21,645 shares of Alexion Pharmaceuticals worth $2.69M as of Q2 2018.
  • PEAK6 Group bought 6,446 Alexion Pharmaceuticals shares in Q2 2018, an estimated $753K.
  • Alexion Pharmaceuticals made up 0.01% of PEAK6 Group's portfolio in Q2 2018, its #1144 holding.
  • PEAK6 Group first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 17 quarters since.
  • PEAK6 Group's Alexion Pharmaceuticals position peaked at $9.11M in Q2 2017.
  • 600 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2018.

Based on PEAK6 Group's 13F filing for Q2 2018, filed 15 Aug 2018.